DPP-4-话题@MedSci

#DPP-4#

57篇内容 | 2194人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1401975, encodeId=7a0714019e5f7, content=<a href='/topic/show?id=7ff0621125' target=_blank style='color:#2F92EE;'>#DPP-4#</a>, objectTitle=【每日播报】-磺脲类药物联合DPP-4抑制剂的疗效, objectType=article, longId=738851, objectId=9b3ae388512b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9b3ae388512b, replyNumber=0, likeNumber=71, createdTime=2022-09-11, rootId=0, userName=gaoxiaoe, userId=eeb42370314, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9b3ae388512b, moduleTitle=【每日播报】-磺脲类药物联合DPP-4抑制剂的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9b3ae388512b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1401974, encodeId=6ba714019e439, content=<a href='/topic/show?id=7ff0621125' target=_blank style='color:#2F92EE;'>#DPP-4#</a>, objectTitle=Front Pharmacol：2型糖尿病患者使用DPP-4i、GLP-1 RAs和SGLT-2i的骨折风险, objectType=article, longId=736722, objectId=3a36e36722e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3a36e36722e3, replyNumber=0, likeNumber=120, createdTime=2022-08-25, rootId=0, userName=gaoxiaoe, userId=eeb42370314, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3a36e36722e3, moduleTitle=Front Pharmacol：2型糖尿病患者使用DPP-4i、GLP-1 RAs和SGLT-2i的骨折风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3a36e36722e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1401973, encodeId=a35514019e3b5, content=<a href='/topic/show?id=7ff0621125' target=_blank style='color:#2F92EE;'>#DPP-4#</a>, objectTitle=SGLT2抑制剂、DPP-4抑制剂和磺酰脲类药物在糖尿病酮症酸中毒方面的安全性比较, objectType=article, longId=736572, objectId=7caae365721d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7caae365721d, replyNumber=0, likeNumber=57, createdTime=2022-08-24, rootId=0, userName=gaoxiaoe, userId=eeb42370314, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7caae365721d, moduleTitle=SGLT2抑制剂、DPP-4抑制剂和磺酰脲类药物在糖尿病酮症酸中毒方面的安全性比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7caae365721d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1401972, encodeId=3f0514019e26d, content=<a href='/topic/show?id=7ff0621125' target=_blank style='color:#2F92EE;'>#DPP-4#</a>, objectTitle=Cardiovasc Diabetol：使用SGLT2i、GLP1RA和DPP-4抑制剂治疗的2型糖尿病患者发生房颤的风险, objectType=article, longId=735642, objectId=ed39e3564211, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ed39e3564211, replyNumber=0, likeNumber=153, createdTime=2022-08-13, rootId=0, userName=gaoxiaoe, userId=eeb42370314, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ed39e3564211, moduleTitle=Cardiovasc Diabetol：使用SGLT2i、GLP1RA和DPP-4抑制剂治疗的2型糖尿病患者发生房颤的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ed39e3564211)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1401971, encodeId=e1e614019e170, content=<a href='/topic/show?id=7ff0621125' target=_blank style='color:#2F92EE;'>#DPP-4#</a>, objectTitle=Cardiovasc Diabetol：DPP-4抑制剂、GLP-1受体激动剂和SGLT-2抑制剂对心肾结局的影响, objectType=article, longId=723796, objectId=c62be2379617, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c62be2379617, replyNumber=0, likeNumber=53, createdTime=2022-04-09, rootId=0, userName=gaoxiaoe, userId=eeb42370314, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c62be2379617, moduleTitle=Cardiovasc Diabetol：DPP-4抑制剂、GLP-1受体激动剂和SGLT-2抑制剂对心肾结局的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c62be2379617)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1401970, encodeId=f9ea14019e0a2, content=<a href='/topic/show?id=7ff0621125' target=_blank style='color:#2F92EE;'>#DPP-4#</a>, objectTitle=Cardiovasc Diabetol：GLP-1激动剂 vs SGLT-2抑制剂 vs DPP-4抑制剂对T2DM患者心肾结局的影响, objectType=article, longId=301367, objectId=c4b830136e91, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c4b830136e91, replyNumber=0, likeNumber=58, createdTime=2022-03-23, rootId=0, userName=gaoxiaoe, userId=eeb42370314, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c4b830136e91, moduleTitle=Cardiovasc Diabetol：GLP-1激动剂 vs SGLT-2抑制剂 vs DPP-4抑制剂对T2DM患者心肾结局的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c4b830136e91)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1401969, encodeId=d41514019691f, content=<a href='/topic/show?id=7ff0621125' target=_blank style='color:#2F92EE;'>#DPP-4#</a>, objectTitle=JAMA子刊：GLP-1受体激动剂与DPP-4抑制剂的使用与2型糖尿病和晚期慢性肾病患者死亡率的关系, objectType=article, longId=300317, objectId=525d30031e63, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=525d30031e63, replyNumber=0, likeNumber=111, createdTime=2022-03-10, rootId=0, userName=gaoxiaoe, userId=eeb42370314, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=525d30031e63, moduleTitle=JAMA子刊：GLP-1受体激动剂与DPP-4抑制剂的使用与2型糖尿病和晚期慢性肾病患者死亡率的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=525d30031e63)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1401968, encodeId=7e70140196829, content=<a href='/topic/show?id=7ff0621125' target=_blank style='color:#2F92EE;'>#DPP-4#</a>, objectTitle=Clin Pharmacol Ther ：2型糖尿病患者中GLP-1 RA和DPP-4抑制剂的使用与肠梗阻风险增加相关, objectType=article, longId=218302, objectId=3ada21830258, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3ada21830258, replyNumber=0, likeNumber=74, createdTime=2021-10-11, rootId=0, userName=gaoxiaoe, userId=eeb42370314, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3ada21830258, moduleTitle=Clin Pharmacol Ther ：2型糖尿病患者中GLP-1 RA和DPP-4抑制剂的使用与肠梗阻风险增加相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3ada21830258)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1401967, encodeId=2898140196eaa, content=<a href='/topic/show?id=7ff0621125' target=_blank style='color:#2F92EE;'>#DPP-4#</a>, objectTitle=BMJ子刊：基于真实世界研究，长期使用DPP-4抑制剂对2型糖尿病患者的安全性和有效性, objectType=article, longId=205874, objectId=7eb72058e492, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7eb72058e492, replyNumber=0, likeNumber=129, createdTime=2021-01-20, rootId=0, userName=gaoxiaoe, userId=eeb42370314, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7eb72058e492, moduleTitle=BMJ子刊：基于真实世界研究，长期使用DPP-4抑制剂对2型糖尿病患者的安全性和有效性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7eb72058e492)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1401966, encodeId=15ec140196676, content=<a href='/topic/show?id=7ff0621125' target=_blank style='color:#2F92EE;'>#DPP-4#</a>, objectTitle=Diabetes Obes Metab：2型糖尿病患者服用DPP-4抑制剂与肺炎风险的关系, objectType=article, longId=198041, objectId=482f198041a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=482f198041a4, replyNumber=0, likeNumber=67, createdTime=2020-07-27, rootId=0, userName=gaoxiaoe, userId=eeb42370314, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=482f198041a4, moduleTitle=Diabetes Obes Metab：2型糖尿病患者服用DPP-4抑制剂与肺炎风险的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=482f198041a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1401965, encodeId=86e01401965d1, content=<a href='/topic/show?id=7ff0621125' target=_blank style='color:#2F92EE;'>#DPP-4#</a>, objectTitle=Metabolism：DPP-4抑制剂在2型糖尿病治疗中的疗效和安全性, objectType=article, longId=196067, objectId=8fa119606e77, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8fa119606e77, replyNumber=0, likeNumber=88, createdTime=2020-06-19, rootId=0, userName=gaoxiaoe, userId=eeb42370314, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8fa119606e77, moduleTitle=Metabolism：DPP-4抑制剂在2型糖尿病治疗中的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8fa119606e77)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1401964, encodeId=31281401964da, content=<a href='/topic/show?id=7ff0621125' target=_blank style='color:#2F92EE;'>#DPP-4#</a>, objectTitle=Diabetes Obes Metab：2型糖尿病患者DPP-4抑制剂治疗与COVID-19, objectType=article, longId=194932, objectId=a64319493248, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a64319493248, replyNumber=0, likeNumber=83, createdTime=2020-05-30, rootId=0, userName=gaoxiaoe, userId=eeb42370314, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a64319493248, moduleTitle=Diabetes Obes Metab：2型糖尿病患者DPP-4抑制剂治疗与COVID-19, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a64319493248)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1401963, encodeId=164c140196344, content=<a href='/topic/show?id=7ff0621125' target=_blank style='color:#2F92EE;'>#DPP-4#</a>, objectTitle=DPP-4抑制剂临床应用专家指导建议解读 | CDS2019, objectType=article, longId=183694, objectId=83b71836947d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=83b71836947d, replyNumber=0, likeNumber=94, createdTime=2019-11-29, rootId=0, userName=gaoxiaoe, userId=eeb42370314, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=83b71836947d, moduleTitle=DPP-4抑制剂临床应用专家指导建议解读 | CDS2019, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=83b71836947d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1401962, encodeId=d62a14019624d, content=<a href='/topic/show?id=7ff0621125' target=_blank style='color:#2F92EE;'>#DPP-4#</a>, objectTitle=客官厉害了！国产原创DPP-4抑制剂盛格列汀“免二进三”, objectType=article, longId=183020, objectId=e12c1830202d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e12c1830202d, replyNumber=0, likeNumber=84, createdTime=2019-11-16, rootId=0, userName=gaoxiaoe, userId=eeb42370314, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e12c1830202d, moduleTitle=客官厉害了！国产原创DPP-4抑制剂盛格列汀“免二进三”, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e12c1830202d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1401961, encodeId=47c8140196110, content=<a href='/topic/show?id=7ff0621125' target=_blank style='color:#2F92EE;'>#DPP-4#</a>, objectTitle=DPP-4抑制剂——心血管疾病史患者的二联用药优选, objectType=article, longId=177142, objectId=867b1e714287, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=867b1e714287, replyNumber=0, likeNumber=50, createdTime=2019-08-09, rootId=0, userName=gaoxiaoe, userId=eeb42370314, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=867b1e714287, moduleTitle=DPP-4抑制剂——心血管疾病史患者的二联用药优选, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=867b1e714287)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1401960, encodeId=a50c1401960f9, content=<a href='/topic/show?id=7ff0621125' target=_blank style='color:#2F92EE;'>#DPP-4#</a>, objectTitle=DPP-4抑制剂——二联用药中的换药优选, objectType=article, longId=176240, objectId=7a4b1e6240bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7a4b1e6240bd, replyNumber=0, likeNumber=92, createdTime=2019-07-28, rootId=0, userName=gaoxiaoe, userId=eeb42370314, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7a4b1e6240bd, moduleTitle=DPP-4抑制剂——二联用药中的换药优选, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7a4b1e6240bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1401959, encodeId=f645140195917, content=<a href='/topic/show?id=7ff0621125' target=_blank style='color:#2F92EE;'>#DPP-4#</a>, objectTitle=为什么DPP-4抑制剂是二甲双胍加药的优选？, objectType=article, longId=176161, objectId=26211e6161fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=26211e6161fd, replyNumber=0, likeNumber=93, createdTime=2019-07-27, rootId=0, userName=gaoxiaoe, userId=eeb42370314, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=26211e6161fd, moduleTitle=为什么DPP-4抑制剂是二甲双胍加药的优选？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=26211e6161fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1401958, encodeId=88d4140195845, content=<a href='/topic/show?id=7ff0621125' target=_blank style='color:#2F92EE;'>#DPP-4#</a>, objectTitle=DPP-4抑制剂，二甲双胍加药优选, objectType=article, longId=176117, objectId=73031e611783, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=73031e611783, replyNumber=0, likeNumber=75, createdTime=2019-07-26, rootId=0, userName=gaoxiaoe, userId=eeb42370314, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=73031e611783, moduleTitle=DPP-4抑制剂，二甲双胍加药优选, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=73031e611783)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1401957, encodeId=08b7140195ef3, content=<a href='/topic/show?id=7ff0621125' target=_blank style='color:#2F92EE;'>#DPP-4#</a>, objectTitle=AP&T： DPP-4抑制剂维达列汀可抑制胃调节并增加胰高血糖素样肽-1血浆水平, objectType=article, longId=162307, objectId=fc3b16230e8f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc3b16230e8f, replyNumber=0, likeNumber=122, createdTime=2019-03-15, rootId=0, userName=gaoxiaoe, userId=eeb42370314, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc3b16230e8f, moduleTitle=AP&T： DPP-4抑制剂维达列汀可抑制胃调节并增加胰高血糖素样肽-1血浆水平, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fc3b16230e8f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1401956, encodeId=3e6f14019566c, content=<a href='/topic/show?id=7ff0621125' target=_blank style='color:#2F92EE;'>#DPP-4#</a>, objectTitle=DPP-4抑制剂临床应用专家共识, objectType=article, longId=157552, objectId=86a515e552ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=86a515e552ea, replyNumber=0, likeNumber=57, createdTime=2019-01-09, rootId=0, userName=gaoxiaoe, userId=eeb42370314, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=86a515e552ea, moduleTitle=DPP-4抑制剂临床应用专家共识, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=86a515e552ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

DPP-4

2020-05-29

gaoxiaoe (审核中...)

前往app查看评论内容

#DPP-4#

【每日播报】-磺脲类药物联合DPP-4抑制剂的疗效

2022-09-11

gaoxiaoe (审核中...)

前往app查看评论内容

#DPP-4#

Front Pharmacol：2型糖尿病患者使用DPP-4i、GLP-1 RAs和SGLT-2i的骨折风险

2022-08-25

gaoxiaoe (审核中...)

前往app查看评论内容

#DPP-4#

SGLT2抑制剂、DPP-4抑制剂和磺酰脲类药物在糖尿病酮症酸中毒方面的安全性比较

2022-08-24

gaoxiaoe (审核中...)

前往app查看评论内容

#DPP-4#

Cardiovasc Diabetol：使用SGLT2i、GLP1RA和DPP-4抑制剂治疗的2型糖尿病患者发生房颤的风险

2022-08-13

gaoxiaoe (审核中...)

前往app查看评论内容

#DPP-4#

Cardiovasc Diabetol：DPP-4抑制剂、GLP-1受体激动剂和SGLT-2抑制剂对心肾结局的影响

2022-04-09

gaoxiaoe (审核中...)

前往app查看评论内容

#DPP-4#

Cardiovasc Diabetol：GLP-1激动剂 vs SGLT-2抑制剂 vs DPP-4抑制剂对T2DM患者心肾结局的影响

2022-03-23

gaoxiaoe (审核中...)

前往app查看评论内容

#DPP-4#

JAMA子刊：GLP-1受体激动剂与DPP-4抑制剂的使用与2型糖尿病和晚期慢性肾病患者死亡率的关系

2022-03-10

gaoxiaoe (审核中...)

前往app查看评论内容

#DPP-4#

Clin Pharmacol Ther ：2型糖尿病患者中GLP-1 RA和DPP-4抑制剂的使用与肠梗阻风险增加相关

2021-10-11

gaoxiaoe (审核中...)

前往app查看评论内容

#DPP-4#

BMJ子刊：基于真实世界研究，长期使用DPP-4抑制剂对2型糖尿病患者的安全性和有效性

2021-01-20

gaoxiaoe (审核中...)

前往app查看评论内容

#DPP-4#

Diabetes Obes Metab：2型糖尿病患者服用DPP-4抑制剂与肺炎风险的关系

2020-07-27

gaoxiaoe (审核中...)

前往app查看评论内容

#DPP-4#

Metabolism：DPP-4抑制剂在2型糖尿病治疗中的疗效和安全性

2020-06-19

gaoxiaoe (审核中...)

前往app查看评论内容

#DPP-4#

Diabetes Obes Metab：2型糖尿病患者DPP-4抑制剂治疗与COVID-19

2020-05-30

gaoxiaoe (审核中...)

前往app查看评论内容

#DPP-4#

DPP-4抑制剂临床应用专家指导建议解读 | CDS2019

2019-11-29

gaoxiaoe (审核中...)

前往app查看评论内容

#DPP-4#

客官厉害了！国产原创DPP-4抑制剂盛格列汀“免二进三”

2019-11-16

gaoxiaoe (审核中...)

前往app查看评论内容

#DPP-4#

DPP-4抑制剂——心血管疾病史患者的二联用药优选

2019-08-09

gaoxiaoe (审核中...)

前往app查看评论内容

#DPP-4#

DPP-4抑制剂——二联用药中的换药优选

2019-07-28

gaoxiaoe (审核中...)

前往app查看评论内容

#DPP-4#

为什么DPP-4抑制剂是二甲双胍加药的优选？

2019-07-27

gaoxiaoe (审核中...)

前往app查看评论内容

#DPP-4#

DPP-4抑制剂，二甲双胍加药优选

2019-07-26

gaoxiaoe (审核中...)

前往app查看评论内容

#DPP-4#

AP&T： DPP-4抑制剂维达列汀可抑制胃调节并增加胰高血糖素样肽-1血浆水平

2019-03-15

gaoxiaoe (审核中...)

前往app查看评论内容

#DPP-4#

DPP-4抑制剂临床应用专家共识

2019-01-09

科室
- - 订阅+
  - 更多科室
工具
服务